Two Myeloma Drugs, One Cap: Part B Leaves 20% Uncapped

A Medicare patient on a two-drug myeloma regimen hits the $2,100 annual out-of-pocket cap on his Part D pill but remains liable for 20% coinsurance on the infused drug in the same regimen all year, because Part B carries no out-of-pocket maximum.

A myeloma patient reaches the point in the year where his Medicare drug plan stops charging him. The pill he takes at home has hit the Part D out-of-pocket ceiling of $2,100, and every fill after that costs him nothing. Then the statement arrives from the oncology clinic, and the number on it is still climbing. Same disease, same treatment plan, same doctor. Different part of Medicare.

The second drug in his regimen is infused in a clinical setting. That puts it under Part B, not Part D — and Part B has no annual limit on what a beneficiary pays. The standard 20% coinsurance applies to the first infusion of January and the last infusion of December, and to every one in between.

Why one drug caps and the other does not

Medicare splits drug coverage by how a medicine is administered rather than by what it treats. Drugs a patient swallows at home generally sit in Part D, the prescription benefit run through private insurers. Drugs a clinician administers — infusions, injections given in a physician's office or hospital outpatient department — are billed under Part B, the medical benefit.

That distinction was an administrative convenience long before it was a financial one. It became a financial one when Congress rebuilt Part D's cost structure and put a hard annual ceiling on what enrollees pay out of pocket, now $2,100. Nothing equivalent was done to Part B. Original Medicare's medical side still works the way it did in 1965: after the deductible, the beneficiary owes 20% of the approved amount, indefinitely.

For most conditions the asymmetry is invisible. For cancer it is not, because oncology regimens routinely pair an oral agent with an infused one. The patient experiences a single course of treatment. The billing system sees two unrelated benefits with two unrelated rules, as 24/7 Wall St laid out in the case of this myeloma patient.

What 20% means when the drug is an infused biologic

Twenty percent sounds like a manageable share. It is manageable when the underlying charge is a routine office visit. It is a different proposition when the underlying charge is a specialty biologic delivered on a repeating schedule, because the coinsurance is a percentage of whatever Medicare approves — and the patient's exposure scales directly with the price of the drug and the number of times it is given.

The structural point matters more than any single dollar figure: because there is no cap, the patient's Part B liability for the year is a function of how long he stays on treatment. A regimen that works well and continues for twelve months costs him more than one discontinued in March. The financial penalty runs in the wrong direction relative to the clinical outcome.

That is the trap the $2,100 Part D ceiling can obscure. A beneficiary who reads about the cap reasonably concludes that Medicare now limits annual drug spending. It limits Part D drug spending. It says nothing about the infusion suite.

The coverage choices that close the gap

Nothing in Original Medicare caps Part B coinsurance. The exposure has to be closed from outside, and there are three broad routes, each with its own trade-offs.

• Medigap (Medicare Supplement). These private policies are designed precisely to pay the 20% that Original Medicare leaves behind. For a patient facing open-ended Part B coinsurance on a biologic, this is the most direct fix. The catch is timing: guaranteed-issue rights are strongest during the initial Medigap open enrollment window after enrolling in Part B. Outside it, in most states an insurer can medically underwrite — and a myeloma diagnosis is exactly the history that underwriting looks for. A patient who declined Medigap at 65 while healthy may find the door narrower after diagnosis.
• Medicare Advantage. Part C plans replace Original Medicare and are required to have an annual out-of-pocket maximum for in-network Part A and Part B services. That maximum is the cap Original Medicare lacks. The trade-off is network restriction and prior authorization — real considerations when a patient wants a specific cancer center and a specific infusion schedule.
• Manufacturer and foundation assistance. Drugmakers run patient assistance programs, and independent charitable foundations offer diagnosis-specific funds that can cover coinsurance for Medicare beneficiaries. Eligibility is income-tested and funds open and close through the year, so this is a supplement to a coverage strategy, not a substitute for one.

Medicaid, for those who qualify, and state pharmaceutical assistance programs sit alongside these. So does the question of site of care: the same infusion can carry a different approved amount in a hospital outpatient department than in a freestanding physician office, and 20% of a smaller number is a smaller number. That is a conversation to have with the practice's financial navigator before treatment starts, not after the statements arrive.

The decision that gets made years before the diagnosis

The uncomfortable part of this story is that the most valuable move — securing a Medigap policy during the initial enrollment window — has to be made by someone who has no idea they will ever need it. Healthy 65-year-olds compare premiums and reasonably choose the cheaper option. The bill for that choice arrives, if it arrives at all, years later and in a form nobody modeled.

Anyone already enrolled and already on an infused therapy should treat the following as the immediate checklist: confirm which part of Medicare each drug in the regimen falls under; ask the clinic's billing office for a written estimate of the annual Part B coinsurance at the planned schedule; check state rules on Medigap underwriting, since a minority of states require guaranteed issue outside the initial window; and ask whether the manufacturer of the infused drug runs an assistance program the practice already works with.

The policy question sits above all of it. Congress capped what a Medicare beneficiary pays for pills and left the infusion side untouched. Until that is addressed, patients whose treatment happens to be delivered through a needle rather than a bottle will keep discovering that the cap they read about does not apply to them — usually in the middle of the year, usually from a statement, and usually too late to change coverage until the next enrollment period.

Frequently asked questions

Why does the $2,100 cap not apply to my infusion?

The $2,100 ceiling is a Part D limit, and Part D covers prescriptions you fill and take at home. Drugs administered by a clinician — infusions and office-administered injections — are billed under Part B, the medical benefit. Part B has no annual out-of-pocket maximum, so the standard 20% coinsurance continues for as long as treatment continues.

What is the difference between Medicare Part B and Part D drug coverage?

Part D is the outpatient prescription benefit delivered through private drug plans and now carries an annual out-of-pocket cap of $2,100. Part B is Medicare's medical benefit and covers drugs a provider administers to you, typically infusions. Part B applies 20% coinsurance after the deductible with no ceiling on what you can pay in a year.

Can Medigap cover the 20% Part B coinsurance?

Yes — that is what Medicare Supplement policies are built to do. They pay some or all of the coinsurance Original Medicare leaves to the beneficiary. The obstacle is enrollment timing: guaranteed-issue protection is strongest during the initial Medigap open enrollment window after you sign up for Part B. Later applications can face medical underwriting in most states.

Does Medicare Advantage cap out-of-pocket costs on infusions?

Medicare Advantage plans are required to have an annual out-of-pocket maximum covering in-network Part A and Part B services, which does put a ceiling on infusion coinsurance. The trade-offs are provider networks and prior authorization requirements, which can matter a great deal if you want a specific cancer center or a specific treatment schedule.

Does where I get the infusion change what I pay?

It can. The Medicare-approved amount for the same drug and administration can differ between a hospital outpatient department and a freestanding physician office. Because your share is a percentage of that approved amount, a lower approved amount means a lower dollar cost to you. Ask the practice's financial navigator to compare sites before treatment begins.

What help exists if I cannot afford the Part B coinsurance?

Drug manufacturers run patient assistance programs, and independent charitable foundations maintain diagnosis-specific funds that can cover coinsurance for Medicare beneficiaries. Eligibility is generally income-tested and foundation funds open and close during the year. Medicaid and state pharmaceutical assistance programs may also apply depending on income and state of residence.

Sources

• His Part D Drug Costs Stop at $2,100. The Infusion in the Same Myeloma Regimen Can Keep Billing Him 20% All Year. — 24/7 Wall St

Photo: Tima Miroshnichenko · Pexels Licence — source